UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Review of trials currently testing treatment and prevention of COVID-19

Clinical microbiology and infection, 2020-08, Vol.26 (8), p.988-998

2020

Volltextzugriff (PDF)

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

CPT: pharmacometrics and systems pharmacology, 2017-02, Vol.6 (2), p.87-109

2017

Volltextzugriff (PDF)

Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features

Clinical microbiology and infection, 2011-04, Vol.17 (4), p.557-565

2011

Volltextzugriff (PDF)

High acquisition rate of extended-spectrum β-lactamase-producing Enterobacteriaceae among French military personnel on mission abroad, without evidence of inter-individual transmission

Clinical microbiology and infection, 2019-05, Vol.25 (5), p.631.e1-631.e9

2019

Volltextzugriff (PDF)

Lewis Sheiner ISoP/UCSF Lecturer Award: From Drug Use to Statistical Models and Vice Versa

CPT: pharmacometrics and systems pharmacology, 2014-12, Vol.3 (12), p.1-4

Mentré, F

2014

Volltextzugriff (PDF)

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

British journal of clinical pharmacology, 2007-11, Vol.64 (5), p.603-612

2007

Volltextzugriff (PDF)

Escherichia coli bacteraemia in pregnant women is life-threatening for foetuses

Clinical microbiology and infection, 2014-12, Vol.20 (12), p.O1035-O1041

2014

Volltextzugriff (PDF)

Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008–2009 winter

Clinical microbiology and infection, 2013-02, Vol.19 (2), p.196-203

2013

Volltextzugriff (PDF)

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

CPT: pharmacometrics and systems pharmacology, 2013-06, Vol.2 (6), p.1-2

2013

Volltextzugriff (PDF)

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study

The European respiratory journal, 2012-03, Vol.39 (3), p.772-775

2012

Volltextzugriff (PDF)

Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics

CPT: pharmacometrics and systems pharmacology, 2014-04, Vol.3 (4), p.1-9

2014

Volltextzugriff (PDF)

Best Practices in Population Modeling Should Always Be Evolving

CPT: pharmacometrics and systems pharmacology, 2013-07, Vol.2 (7), p.1-2

2013

Volltextzugriff (PDF)

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

CPT: pharmacometrics and systems pharmacology, 2015-06, Vol.4 (6), p.316-319

2015

Volltextzugriff (PDF)

Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome

CPT: pharmacometrics and systems pharmacology, 2013-07, Vol.2 (7), p.1-9

2013

Volltextzugriff (PDF)

A Model‐Based Illustrative Exploratory Approach to Optimize the Dosing of Peg‐IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy

CPT: pharmacometrics and systems pharmacology, 2015-01, Vol.4 (1), p.37-40

2015

Volltextzugriff (PDF)

Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV‐infected patients

HIV medicine, 2004-07, Vol.5 (4), p.307-313

2004

Volltextzugriff (PDF)

Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV‐infected patients on HAART

British journal of clinical pharmacology, 2005-10, Vol.60 (4), p.390-403

2005

Volltextzugriff (PDF)

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study: Table 1

The European respiratory journal, 2012-03, Vol.39 (3), p.772-775

2012

Volltextzugriff (PDF)

Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method

British journal of clinical pharmacology, 1997-11, Vol.44 (5), p.447-453

1997

Volltextzugriff (PDF)

Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients

British journal of clinical pharmacology, 2008-04, Vol.65 (4), p.548-557

2008

Volltextzugriff (PDF)

Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6‐an evaluation with the nonparametric maximum likelihood method

British journal of clinical pharmacology, 1994-11, Vol.38 (5), p.453-462

1994

Volltextzugriff (PDF)

Risk factors for Staphylococcus aureus infection in liver transplant recipients

Liver transplantation, 2005-09, Vol.11 (9), p.1093-1099

2005

Volltextzugriff (PDF)

Cerebral uptake of mefloquine enantiomers with and without the P‐gp inhibitor elacridar (GF1210918) in mice

British journal of pharmacology, 2004-04, Vol.141 (7), p.1214-1222

2004

Volltextzugriff (PDF)

Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients

British journal of clinical pharmacology, 2005-01, Vol.59 (1), p.18-27

2005

Volltextzugriff (PDF)

Action COST B15 : Modelling during drug development October 1998 to July 2004

Basic & clinical pharmacology & toxicology, 2005-03, Vol.96 (3), p.149-150

BALANT, Luc

2005

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

ThemaPhysical Sciences

KollektionElectronic Journals Library

KollektionWiley Online Library Journals Frontfile Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Review of trials currently testing treatment and prevention of COVID-19

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features

High acquisition rate of extended-spectrum β-lactamase-producing Enterobacteriaceae among French military personnel on mission abroad, without evidence of inter-individual transmission

Lewis Sheiner ISoP/UCSF Lecturer Award: From Drug Use to Statistical Models and Vice Versa

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

Escherichia coli bacteraemia in pregnant women is life-threatening for foetuses

Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008–2009 winter

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study

Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics

Best Practices in Population Modeling Should Always Be Evolving

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome

A Model‐Based Illustrative Exploratory Approach to Optimize the Dosing of Peg‐IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy

Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV‐infected patients

Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV‐infected patients on HAART

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study: Table 1

Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method

Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients

Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6‐an evaluation with the nonparametric maximum likelihood method

Risk factors for Staphylococcus aureus infection in liver transplant recipients

Cerebral uptake of mefloquine enantiomers with and without the P‐gp inhibitor elacridar (GF1210918) in mice

Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients

Action COST B15 : Modelling during drug development October 1998 to July 2004

Aktive Filter

Suchergebnisse filtern